12,517 Shares in Jazz Pharmaceuticals PLC $JAZZ Purchased by Clough Capital Partners L P

Clough Capital Partners L P acquired a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) in the 4th quarter, Holdings Channel.com reports. The firm acquired 12,517 shares of the specialty pharmaceutical company’s stock, valued at approximately $2,128,000.

Other institutional investors have also recently bought and sold shares of the company. Hilltop National Bank acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $36,000. LRI Investments LLC acquired a new position in Jazz Pharmaceuticals during the fourth quarter worth about $38,000. Danske Bank A S acquired a new position in Jazz Pharmaceuticals during the third quarter worth about $40,000. Geneos Wealth Management Inc. raised its stake in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in Jazz Pharmaceuticals by 1,383.3% during the third quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 332 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock opened at $226.93 on Thursday. The business has a 50 day moving average of $220.08 and a 200-day moving average of $189.96. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $243.32. The company has a debt-to-equity ratio of 0.95, a current ratio of 2.04 and a quick ratio of 1.85. The company has a market capitalization of $14.26 billion, a P/E ratio of -11,340.83, a P/E/G ratio of 0.20 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last released its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The company had revenue of $1.07 billion during the quarter. On average, equities research analysts predict that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mark Douglas Smith sold 1,157 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total value of $266,746.35. Following the completion of the transaction, the director owned 9,680 shares of the company’s stock, valued at $2,231,724. This represents a 10.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Heather Ann Mcsharry sold 2,000 shares of the company’s stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the transaction, the director directly owned 18,449 shares of the company’s stock, valued at $4,446,209. This represents a 9.78% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 13,098 shares of company stock valued at $2,832,086 over the last three months. Insiders own 4.10% of the company’s stock.

Trending Headlines about Jazz Pharmaceuticals

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz announced a major research collaboration and licensing deal with AbCellera to discover and develop next-generation T-cell engaging multispecific antibodies for cancer, including solid tumors. The agreement could be worth up to roughly $820 million to $876 million per drug if milestones are achieved, signaling a potentially meaningful new pipeline opportunity. Article: Jazz Pharma, AbCellera ink antibody deal worth up to $876 million
• Positive Sentiment: Jazz also released extensive late-breaking data at SLEEP 2026 showing real-world benefits of Xywav in narcolepsy and idiopathic hypersomnia, including evidence of improved patient outcomes and possible cardiometabolic benefits linked to reduced sodium exposure. That supports the company’s commercial franchise and may reinforce confidence in a core revenue driver. Article: Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026
• Neutral Sentiment: A director disclosed a planned sale of 1,157 shares under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes attract attention, the small size and scheduled nature make it unlikely to be a major fundamental concern. Article: SEC filing for director sale

Analysts Set New Price Targets

Several brokerages have commented on JAZZ. Morgan Stanley reissued an “overweight” rating and set a $245.00 target price on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Raymond James Financial reissued an “outperform” rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, May 6th. Leerink Partners boosted their target price on Jazz Pharmaceuticals from $215.00 to $225.00 and gave the stock an “outperform” rating in a research note on Wednesday, April 22nd. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $188.00 to $307.00 in a research note on Tuesday, May 19th. Finally, Barclays boosted their target price on Jazz Pharmaceuticals from $234.00 to $253.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 27th. Sixteen analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $246.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.